|
[Related PubMed/MEDLINE]
Total Number of Papers: 99
|
|
|
|
|
[Display Entries]
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
|
Page: of
|
|
|
|
| Abbreviation |
: FACT-P |
| Long Form |
: Functional Assessment of Cancer Therapy-Prostate |
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2020 |
Does trunk muscle training with an oscillating rod improve urinary incontinence after radical prostatectomy? A prospective randomized controlled trial. |
CG, HRQL, IG |
| 2 |
2020 |
Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study. |
ADT, HRQoL, mHSPC, PROs, QLQ-PR25, rPFS |
| 3 |
2020 |
Health-related Quality of Life in Patients with Advanced Prostate Cancer: A Systematic Review. |
EQ-5D, HRQoL, PCa, PRISMA |
| 4 |
2020 |
Matching-Adjusted Indirect Comparison of Health-Related Quality of Life and Adverse Events of Apalutamide Versus Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer. |
ADT, AEs, HRQoL, MAIC, nmCRPC, ORs |
| 5 |
2020 |
Open Label Phase II Study of Enzalutamide With Concurrent Administration of Radium 223 Dichloride in Patients With Castration-Resistant Prostate Cancer. |
AEs, BPI-SF, CRPC, Ra 223 |
| 6 |
2020 |
Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study. |
BPI-SF, CARD, ECOG, EQ-5D-5L, HR, PROs |
| 7 |
2020 |
Real-world evidence in patient-reported outcomes (PROs) of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate + prednisone (AA+P) across Canada: Final results of COSMiC. |
BFI, BPI-SF, CHS-PCa, mCRPC, MoCA, PROs, PSA, SD |
| 8 |
2019 |
Adjuvant hormone therapy after radical prostatectomy in high-risk localized and locally advanced prostate cancer: First multicenter, observational study in China. |
AA, CAB, cT2, HT, LHRHa, PCa, PSA, pT3, QOL, RP |
| 9 |
2019 |
Ambulatory Robot-Assisted Laparoscopic Prostatectomy: Is It Ready for Prime Time? A Quality of Life Analysis. |
CT, EWB, FACT-G, NDD, PIS, PSS, QOL, RALP |
| 10 |
2019 |
An observational, multicentre study of cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (CAPRISTANA). |
AE, CAPRISTANA, HRQoL, mCRPC, OS, PFS, TTF |
| 11 |
2019 |
Fatigue, quality of life and metabolic changes in men treated with first-line enzalutamide versus abiraterone plus prednisolone for metastatic castration-resistant prostate cancer (HEAT): a randomised trial protocol. |
AAP, HRQoL, mCRPC |
| 12 |
2019 |
Health utility and health-related quality of life of Japanese prostate cancer patients according to progression status measured using EQ-5D-5L and FACT-P. |
CRPC, DM, EQ-5D-5L, EQ-VAS, GLM, HRQoL, LP, PC |
| 13 |
2019 |
Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study. |
ADT, BFI, BPI-SF, EQ-5D-5L, HRQoL, TITAN |
| 14 |
2019 |
Health-Related Quality of Life and Its Associated Factors in Prostate Cancer Patients Who Receive Androgen Deprivation Therapy. |
ADT, HRQoL |
| 15 |
2019 |
Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial. |
HRQoL, MMRM, MoCA, PHQ-9 |
| 16 |
2019 |
Home-based 'exergaming' was safe and significantly improved 6-min walking distance in patients with prostate cancer: a single-blinded randomised controlled trial. |
6MWT, ADT, FACT-F, LEP, QOL |
| 17 |
2019 |
Investigating the relationships between quality of life, fatigue and leisure time physical activity in prostate cancer patients. |
FACIT-F, GLTEQ, PCa |
| 18 |
2019 |
Meaningful differences and validity for the NCCN/FACT-P Symptom Index: An analysis of the ALSYMPCA data. |
NFPSI-17 |
| 19 |
2019 |
Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial. |
BPI-SF, HR |
| 20 |
2019 |
Quality of life among patients after cystoprostatectomy as the treatment for locally advanced prostate cancer with bladder invasion. |
LAPC, QOL |
| 21 |
2019 |
Quality-of-Life Assessment and Reporting in Prostate Cancer: Systematic Review of Phase 3 Trials Testing Anticancer Drugs Published Between 2012 and 2018. |
CRPC, QOL |
| 22 |
2019 |
Treatment Experiences, Information Needs, Pain and Quality of Life in Men with Metastatic Castrate-resistant Prostate Cancer: Results from the EXTREQOL Study. |
mCRPC, QOL, TOI |
| 23 |
2018 |
A mini-review of quality of life as an outcome in prostate cancer trials: patient-centered approaches are needed to propose appropriate treatments on behalf of patients. |
HRQoL, PC, QALYs |
| 24 |
2018 |
A Phase II, Randomized, Multicenter Study Comparing 10 Months versus 4 Months of Degarelix Therapy in Prolonging the Off Treatment Interval in Men with Localized Prostate Cancer Receiving Intermittent Androgen Deprivation Therapy for Biochemical Recurrence following Radical Local Therapy. |
IPSS |
| 25 |
2018 |
Detailed analysis of patient-reported lower urinary tract symptoms and effect on quality of life after robotic radical prostatectomy. |
HRQoL, ICIQ-MLUTS, LUTS, RARP, SD |
| 26 |
2018 |
Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial. |
HRQoL |
| 27 |
2018 |
Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. |
ADT, BFI, BPI-SF, ECOG, HR, HRQoL, PROs |
| 28 |
2018 |
Perceptions of masculinity and body image in men with prostate cancer: the role of exercise. |
BIS, GLTEQ, MSES, PAQ |
| 29 |
2018 |
Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer. |
ADT, QOL |
| 30 |
2018 |
Shared Decision-Making in Patients With Prostate Cancer in Japan: Patient Preferences Versus Physician Perceptions. |
PCa, SDM |
| 31 |
2017 |
A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy. |
BPI, EQ-5D, OS, rPFS, TEAE |
| 32 |
2017 |
A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy. |
BPI, EQ-5D, OS, rPFS, TEAE |
| 33 |
2017 |
Impact of Enzalutamide Compared with Bicalutamide on Quality of Life in Men with Metastatic Castration-resistant Prostate Cancer: Additional Analyses from the TERRAIN Randomised Clinical Trial. |
EQ-5D, HRQoL, mCRPC |
| 34 |
2017 |
Impact of symptomatic skeletal events on health-care resource utilization and quality of life among patients with castration-resistant prostate cancer and bone metastases. |
BPI-SF, CRPC, ES, HRQoL, HRU, IRR, SSEs |
| 35 |
2017 |
Predictors of health-related quality of life in Korean prostate cancer patients receiving androgen deprivation therapy. |
ADT, FACIT-F, HADS, HRQoL |
| 36 |
2017 |
Quality of Life in Second-Line Treatment of Metastatic Castration-Resistant Prostate Cancer Using Cabazitaxel or Other Therapies After Previous Docetaxel Chemotherapy: Swiss Observational Treatment Registry. |
mCRPC, OT, QOL |
| 37 |
2017 |
Skeletal-related events significantly impact health-related quality of life in metastatic castration-resistant prostate cancer: data from PREVAIL and AFFIRM trials. |
CI, HRQoL, mCRPC, SREs |
| 38 |
2017 |
The association between health-related quality-of-life scores and clinical outcomes in metastatic castration-resistant prostate cancer patients: Exploratory analyses of AFFIRM and PREVAIL studies. |
CIs, HRQoL, HRs, mCRPC, MID, OS, PREVAIL, rPFS |
| 39 |
2017 |
[Clinical efficacy of integrated traditional Chinese and Western medicine for castration-resistant prostate cancer]. |
CRPC, PSA |
| 40 |
2016 |
"What if…": decisional regret in patients who discontinued active surveillance. |
AS |
| 41 |
2016 |
Erratum to: The internal and external responsiveness of Functional Assessment of Cancer Therapy-Prostate (FACT-P) and Short Form-12 Health Survey version 2 (SF-12 v2) in patients with prostate cancer. |
SF-12v2 |
| 42 |
2016 |
Health-related quality of life of Chinese patients with prostate cancer in comparison to general population and other cancer populations. |
HRQoL, SF-12 v2 |
| 43 |
2016 |
Health-Related Quality of Life, Psychological Distress, and Sexual Changes Following Prostate Cancer: A Comparison of Gay and Bisexual Men with Heterosexual Men. |
GB, HRQoL, PCa |
| 44 |
2016 |
Oncology Section EDGE Task Force on Prostate Cancer: A Systematic Review of Outcome Measures for Health-Related Quality of Life. |
EPIC, FACT-G, HRQoL, SF, UCLA-PCI |
| 45 |
2016 |
Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study. |
CI, CRPC, EQ-5D, OR, QOL, radium-223, SOC |
| 46 |
2016 |
Repeated measures analysis of patient-reported outcomes in prostate cancer after abiraterone acetate. |
HRQoL, mCRPC, PCS, PMM, PROs, TOI |
| 47 |
2016 |
The internal and external responsiveness of Functional Assessment of Cancer Therapy-Prostate (FACT-P) and Short Form-12 Health Survey version 2 (SF-12 v2) in patients with prostate cancer. |
SF-12v2 |
| 48 |
2015 |
Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial. |
BPI-SF, HR, HRQoL |
| 49 |
2015 |
Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. |
EPIC, NCCN, PROs, QOL, SF, UCLA-PCI |
| 50 |
2015 |
Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: additional analyses from the AFFIRM randomized clinical trial. |
CDF, mCRPC, PMM |
| 51 |
2015 |
Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: additional analyses from the AFFIRM randomized clinical trial. |
CDF, mCRPC, PMM |
| 52 |
2015 |
Mapping FACT-P to EQ-5D in a large cross-sectional study of metastatic castration-resistant prostate cancer patients. |
EQ-5D, HRQoL, mCRPC, OLS, SD |
| 53 |
2015 |
Psychometric properties of Functional Assessment of Cancer Therapy-Prostate (FACT-P) in Chinese patients with prostate cancer. |
--- |
| 54 |
2015 |
Temsirolimus Maintenance Therapy After Docetaxel Induction in Castration-Resistant Prostate Cancer. |
CECs, CI, CRPC, PPI, PSA, TTPP, TTTF |
| 55 |
2014 |
A randomised phase 2 study combining LY2181308 sodium (survivin antisense oligonucleotide) with first-line docetaxel/prednisone in patients with castration-resistant prostate cancer. |
BPI, CI, CRPC, OS, PFS, PSA |
| 56 |
2014 |
A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients. |
BAP, BTM, CRPC, PFS, PPI, VEGFR |
| 57 |
2014 |
Lifestyle changes for improving disease-specific quality of life in sedentary men on long-term androgen-deprivation therapy for advanced prostate cancer: a randomised controlled trial. |
ADT, CI, FACT-F, QOL |
| 58 |
2014 |
Mapping the FACT-P to the preference-based EQ-5D questionnaire in metastatic castration-resistant prostate cancer. |
HRQoL |
| 59 |
2013 |
A reference set of health utilities for long-term survivors of prostate cancer: population-based data from Ontario, Canada. |
PC, PCI, QOL |
| 60 |
2013 |
Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. |
BPI-SF, HR, HRQoL |
| 61 |
2013 |
Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy. |
HRQoL, mCRPC |
| 62 |
2013 |
Pain questionnaire performance in advanced prostate cancer: comparative results from two international clinical trials. |
BPI, PPI |
| 63 |
2013 |
Quality of life after radical radiotherapy for prostate cancer: longitudinal study from a randomised trial of external beam radiotherapy alone or in combination with high dose rate brachytherapy. |
EBRT, HDR, TOI |
| 64 |
2011 |
Health-related quality of life in pain-free or mildly symptomatic patients with metastatic hormone-resistant prostate cancer following treatment with the specific endothelin A receptor antagonist zibotentan (ZD4054). |
HRPC, HRQoL |
| 65 |
2011 |
Racial differences in well-being and cancer concerns in prostate cancer patients. |
--- |
| 66 |
2011 |
The association between erectile dysfunction and depressive symptoms in men treated for prostate cancer. |
ED, HADS |
| 67 |
2010 |
Development and validation of the korean version of expanded prostate cancer index composite: questionnaire assessing health-related quality of life after prostate cancer treatment. |
EPIC, PCa, QOL |
| 68 |
2010 |
Late gastrointestinal toxicity after dose-escalated conformal radiotherapy for early prostate cancer: results from the UK Medical Research Council RT01 trial (ISRCTN47772397). |
CFRT, HR, LENT/SOM, RTOG, UCLA-PCI |
| 69 |
2010 |
Prostate cancer: how assessment of QoL can improve delivery of care. |
DH, QOL |
| 70 |
2010 |
Testosterone levels and quality of life in diverse male patients with cancers unrelated to androgens. |
BAT, FT, QOL, SHBG, TT |
| 71 |
2009 |
Estimating clinically meaningful changes for the Functional Assessment of Cancer Therapy--Prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer. |
AE, BAP, CMCs, FAPSI, KPS, PCS, SEM, TOI, TTP |
| 72 |
2009 |
Quality of life in patients with prostate cancer: development and application of a hybrid assessment method. |
QOL |
| 73 |
2008 |
Analysis of health related quality of life (HRQoL) of patients with clinically localized prostate cancer, one year after treatment with external beam radiotherapy (EBRT) alone versus EBRT and high dose rate brachytherapy (HDRBT). |
EBRT, HDR-BT, HRQoL, QOL |
| 74 |
2008 |
Evaluation of quality of life in patients with previously untreated advanced prostate cancer receiving maximum androgen blockade therapy or LHRHa monotherapy: a multicenter, randomized, double-blind, comparative study. |
LHRHa, MAB, QOL |
| 75 |
2008 |
Measuring the individual quality of life of patients with prostate cancer. |
QOL, SEIQoL-DW |
| 76 |
2008 |
Quality of life in men treated with carbon ion therapy for prostate cancer. |
C-ion RT, PCS, PWB, QOL, S/FWB, UCLA-PCI |
| 77 |
2008 |
[Quality of life among patients with advanced prostate cancer: a survey using functional assessment of cancer therapy-prostate in China]. |
FACT-G, PCS |
| 78 |
2007 |
Exercise prevents fatigue and improves quality of life in prostate cancer patients undergoing radiotherapy. |
QOL |
| 79 |
2007 |
Mapping FACT-P and EORTC QLQ-C30 to patient health status measured by EQ-5D in metastatic hormone-refractory prostate cancer patients. |
HRPCA, HRQoL, OLS |
| 80 |
2007 |
Quality of life before and after prostatectomy as treatment for localized cancer. |
--- |
| 81 |
2007 |
Quality of life findings from a multicenter, multinational, observational study of patients with metastatic hormone-refractory prostate cancer. |
HRPC, HRQL |
| 82 |
2006 |
Phase I/II study of weekly docetaxel and vinblastine in the treatment of metastatic hormone-refractory prostate carcinoma. |
--- |
| 83 |
2006 |
Quality of life as a potential predictor for morbidity and mortality in patients with metastatic hormone-refractory prostate cancer. |
HRPC |
| 84 |
2006 |
The Functional Assessment of Cancer Therapy-Prostate (FACT-P) scales in men with prostate cancer: reliability and validity of the Korean version. |
--- |
| 85 |
2006 |
Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancer. |
AIPC, PSA |
| 86 |
2005 |
Health-related quality of life in men receiving prostate brachytherapy on RTOG 98-05. |
HRQoL, HRQOL, IPSS, PB, SAQ, SEM |
| 87 |
2005 |
Longitudinal study of quality of life in patients with localized prostate cancer undergoing radiotherapy. |
BDI, CRT, ESS, MRT, PCS, PFS, PRT, PWB, QOL |
| 88 |
2005 |
Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. |
HRPC, PSA |
| 89 |
2004 |
The 3rd Conference on Asian Trends in Prostate Cancer Hormone Therapy. |
--- |
| 90 |
2003 |
Brief assessment of priority symptoms in hormone refractory prostate cancer: the FACT Advanced Prostate Symptom Index (FAPSI). |
FAPSI, FAPSI-8 |
| 91 |
2003 |
Patient-reported toxicity correlated to dose-volume histograms of the rectum in radiotherapy of the prostate. |
DVHs, QOL, UCLA-PCI |
| 92 |
2003 |
The prevalence and predictors of psychological distress in men with prostate cancer who are seeking support. |
HADS |
| 93 |
2002 |
Quality of life and sexuality of men with prostate cancer 3 years after cryosurgery. |
SFQ |
| 94 |
2001 |
A prospective quality-of-life study in men with clinically localized prostate carcinoma treated with radical prostatectomy, external beam radiotherapy, or interstitial brachytherapy. |
EBRT, HRQoL, IB, RP |
| 95 |
2000 |
A prospective analysis of patient-reported quality of life after prostate brachytherapy. |
IPSS, PB, QOL |
| 96 |
2000 |
Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. |
AUASI, EPIC, HRQoL, UCLA-PCI |
| 97 |
1999 |
Early quality of life assessment in men treated with permanent source interstitial brachytherapy for clinically localized prostate cancer. |
IPSS, IPSS |
| 98 |
1999 |
Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. |
CI, QOL |
| 99 |
1999 |
Quality-of-life outcomes for men treated with cryosurgery for localized prostate carcinoma. |
--- |
|
A Search Service for Abbreviation / Long Form
